(Q45367431)

English

Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy

scientific article published on 20 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

12

object named as

Naoya Sakamoto

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

author name string

Makoto Kadokura

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Shinya Maekawa

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Ryota Sueki

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Mika Miura

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Kazuki Komase

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hiroko Shindo

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Fumitake Amemiya

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Tomoyoshi Uetake

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Taisuke Inoue

9

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Minoru Sakamoto

10

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Mina Nakagawa

11

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Mamoru Watanabe

13

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Nobuyuki Enomoto

14

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

publication date

20 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hepatology international

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

789-799

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

https://scigraph.springernature.com/pub.10.1007/s12072-011-9267-x

0 references

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Clinical relevance of hepatitis C virus genotypes

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS12072-011-9267-X

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21484117

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12072-011-9267-X

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45367431&oldid=2075899191"